Why ALLO Stock dropped -5.60% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, ALLO scores 33 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 7 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and FCF yield of 0%. For a prospective investor, the cash engine is the weakest structural signal: the company is consuming capital rather than generating it, and the rating treats this as the primary drag on the score.
• Whale 13F Flow: 3 / 20. The pillar covers institutional accumulation and options positioning. The lowest-scoring pillar indicates that the source data does not support a constructive institutional accumulation narrative. The source provides no 13F holder detail (see Analyst View section), so the score cannot be decomposed further.
• Insider Conviction: 5 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. A low score signals that insider activity does not provide meaningful conviction support.
• Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. The score indicates limited macro-regime alignment; a beta of 1.0 means the stock moves in line with the broad market rather than offering defensive or asymmetric characteristics.
• Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, the inputs are Altman Z 2.5, Piotroski F 3/9, and Debt/Equity 0.5. The Altman Z-Score sits in a range the rating treats as moderate rather than safe, and the Piotroski F-Score of 3/9 indicates weak fundamental-quality signals.

Investor implications. The rating's weakest pillars are cash generation and institutional/insider flow, which together describe a company with negative returns on capital, no free-cash generation, and no visible sponsorship signal in the provided data. The upside case available from the data is limited to the possibility that the balance sheet and macro pillars improve; the balance sheet pillar is the strongest of the five at 10/20, but still well below half credit. Valuation cannot be assessed on earnings multiples because P/E and EV/EBITDA are not available in source data, and the market-cap-to-cash comparison (see Financial Trend) is the most concrete valuation reference the data supports. The 52-week range of $1.04 to $4.46 and a current price of $1.25 place the stock near the low end of its recent range, which is consistent with the negative rating but does not by itself establish direction.

Allogene Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances), per the company profile. Per the company profile, the market capitalization is $0.4B. The source data does not describe the company's products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M in FY 2025, $0.0M in FY 2024, and $0.1M in FY 2023, indicating no meaningful commercial revenue in the reported periods.

Per the SEC financials, the company reported operating losses in every period shown, with net losses of $-190.9M in FY 2025 and $-257.6M in FY 2024. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash declined from $75.2M in FY 2024 to $51.7M in FY 2025 per the SEC financials, against FCF of $-149.6M in FY 2025, while the debt line is listed as N/A in the SEC financials.

Per the recent news feed, all six items are tagged as market-wire items with a YELLOW signal and reference ALLO. The headlines consist of market-data and aggregator pages (Yahoo Finance Canada, TradingView, MarketBeat, Value Research, and others) and one Investing.com item reporting a CFO sale of $48,698 in stock. The aggregator items carry no substantive operating catalyst detail. Risk watch items from the feed include the insider sale reference and the short-interest update titled for October 2026. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The source data therefore provides no upstream supplier, downstream customer, or cross-sector dependency mapping. The only sector context available is the classification of Health Care / Biotechnology: Biological Products. For a prospective investor, the absence of mapped dependencies means second-order ripple effects cannot be identified from the provided sources; any concentration or partner-dependency risk for a clinical-stage profile of this type would need to be verified from primary filings outside this dataset.

• What is the company's clinical or commercial pipeline, and what milestones are scheduled that could alter the cash-burn trajectory shown in the financials?
• Debt is listed as N/A in the SEC financials while Debt/Equity is 0.5 per the Roarable RQD rating; what instruments make up the liability base, and what are their maturities?
• What is the runway implied by the FY 2025 cash of $51.7M against FY 2025 FCF of $-149.6M, and how will the gap be financed?
• Who holds the shares, and what is the 13F and insider position behind the Whale and Insider pillar scores, given that the holders section is empty?
• What drove the CFO stock sale referenced in the news feed, and does it fall under any pre-arranged trading plan?